Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.

Abstract

This is a summary of the original article: "Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials". Chronic Hand Eczema (CHE) is a heterogeneous, multifactorial, fluctuating, and chronic inflammatory disease associated with pain, itch, and a significant quality-of-life burden for patients. The phase 3 DELTA 1 and DELTA 2 trials assessed the efficacy and safety of twice-daily delgocitinib cream 20 mg/g, a pan-Janus kinase inhibitor, compared with cream vehicle in adults with moderate to severe CHE. Delgocitinib cream demonstrated superior efficacy versus cream vehicle in outcomes reported by clinicians (e.g., Investigator's Global Assessment for CHE [IGA-CHE] treatment success [IGA-CHE 0 (clear)/1 (almost clear)] and ≥75/90% improvement in Hand Eczema Severity Index) and patients (e.g., itch, pain, and Dermatology Life Quality Index). Delgocitinib cream exhibited a favorable safety profile in both trials. These results suggest that delgocitinib cream is a treatment option for the relief of clinical signs and symptoms among patients with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate.